Compare AGL & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGL | INDP |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.5M |
| IPO Year | 2021 | 2021 |
| Metric | AGL | INDP |
|---|---|---|
| Price | $10.74 | $1.60 |
| Analyst Decision | Hold | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $66.48 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 17.3K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,932,576,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.02 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $0.27 |
| 52 Week High | $9.80 | $13.24 |
| Indicator | AGL | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 96.91 | 37.58 |
| Support Level | $0.69 | $0.27 |
| Resistance Level | N/A | $1.99 |
| Average True Range (ATR) | 0.39 | 0.11 |
| MACD | 1.12 | -0.00 |
| Stochastic Oscillator | 97.82 | 7.14 |
Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.